Genomic Features of Response to Combination Immunotherapy in Lung Cancer

被引：17
作者：
Frueh, Martin [1 ]
Peters, Solange [2 ]
机构：
[1] Cantonal Hosp St Gallen, Dept Med Oncol Hematol, St Gallen, Switzerland
[2] Univ Hosp Lausanne CHUV, Dept Med Oncol, CH-1011 Lausanne, Switzerland
来源：
CANCER CELL | 2018年 / 33卷 / 05期
关键词：
NIVOLUMAB PLUS IPILIMUMAB; MUTATIONAL LANDSCAPE; CTLA-4; BLOCKADE; OPEN-LABEL; MELANOMA;
D O I：
10.1016/j.ccell.2018.04.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.
引用
收藏
页码：791 / 793
页数：3
相关论文
共 50 条
  • [41] EGFR TKI combination with immunotherapy in non-small cell lung cancer
    Ahn, Myung-Ju
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 465 - 469
  • [42] Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma
    Li, Peng
    Che, Shuyu
    Qi, Yingxue
    Luo, Ningning
    Lin, Qiuju
    Zhu, Xiaofeng
    Xuan, Yunpeng
    Li, Mengmeng
    Li, Jinlong
    Ge, Minghui
    Sun, Tingting
    Qi, Chuang
    Wang, Yongjie
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 2997 - 3007
  • [43] Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer
    van de Haar, Joris
    Mankor, Joanne M.
    Hummelink, Karlijn
    Monkhorst, Kim
    Smit, Egbert F.
    Wessels, Lodewyk F. A.
    Cuppen, Edwin
    Aerts, Joachim G. J., V
    Voest, Emile E.
    [J]. CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1307 - 1318
  • [44] New advances in immunotherapy for non-small cell lung cancer
    Qin, Haifeng
    Wang, Fang
    Liu, Hui
    Zeng, Zhen
    Wang, Shasha
    Pan, Xin
    Gao, Hongjun
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2018, 10 (08): : 2234 - 2245
  • [45] Molecular Biomarkers of Response to Cancer Immunotherapy
    Ritterhouse, Lauren L.
    Gogakos, Tasos
    [J]. CLINICS IN LABORATORY MEDICINE, 2022, 42 (03) : 469 - 484
  • [46] Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy
    Sereno, Maria
    de Cordoba, Irene Hernandez
    Gutierrez-Gutierrez, Gerardo
    Casado, Enrique
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [47] Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update
    Blons, Helene
    Garinet, Simon
    Laurent-Puig, Pierre
    Oudart, Jean-Baptiste
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 : S25 - S36
  • [48] Combination of bevacizumab and dual immunotherapy for extensive-disease small-cell lung cancer: a case report
    Song, Lei
    Zhou, Rengui
    Li, Xiangyong
    Pan, Dejian
    [J]. IMMUNOTHERAPY, 2021, 13 (16) : 1309 - 1315
  • [49] The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
    Khalil, Danny N.
    Smith, Eric L.
    Brentjens, Renier J.
    Wolchok, Jedd D.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (05) : 273 - 290
  • [50] Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
    Wang, Xue
    Niu, Xiaomin
    An, Na
    Sun, Yile
    Chen, Zhiwei
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
12345